Patient adverse events during treatment (IMAGE)
Caption
In terms of safety, the combination of pyrrolizinib and fulvestrant was well tolerated. No grade 4 adverse events or treatment-related deaths occurred, although adverse effects of grade 3 or higher were reported in 43.5% of the patients. The most common grade 3 adverse event was diarrhea (26.1%), which was not seriously affected by dose modification or symptomatic management (e.g., antidiarrheal drugs). This combination therapy was associated with less severe side effects than conventional chemotherapy, and patients were able to continue treatment without serious adverse effects.
Credit
Ying Wang
Usage Restrictions
Please cite source
License
Original content